Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01444404 · ClinicalTrials.gov registry record · Phase 1
A Study of AMG 820 in Subjects With Advanced Solid Tumors
A Phase 1 study of Cancer and Advanced Solid Tumors, sponsored by AmMax Bio.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
- 3
- Study locations
NCT01444404: Completed Phase 1 study of Cancer and Advanced Solid Tumors, sponsored by AmMax Bio.
NCT01444404 is a Phase 1 study of Cancer and Advanced Solid Tumors that has completed, run by AmMax Bio. The registered enrollment target is 25 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01444404, a Phase 1 study of Cancer and Advanced Solid Tumors, has completed, sponsored by AmMax Bio.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
- 3
- Study locations
Study Summary
First in human, open-label, sequential dose escalation and expansion study of AMG 820 in subjects with advanced solid tumors.
Conditions Studied
Interventions
- DRUG AMG 820
Study Locations (3)
Pennsylvania
- Research Site - Philadelphia
South Carolina
- Research Site - Greenville
Texas
- Research Site - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2008-03-31 |
| Est. Completion | 2014-02-06 |
| Phase | Phase 1 |
What the finished NCT01444404 record still lists
NCT01444404 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower).
The record links to 6 conditions, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which AMG 820 is the first listed.
NCT01444404 reports a single indexed study location in Pennsylvania, South Carolina, Texas.
Frequently Asked Questions
What is clinical trial NCT01444404 about?
NCT01444404 is a clinical study titled "A Study of AMG 820 in Subjects With Advanced Solid Tumors". First in human, open-label, sequential dose escalation and expansion study of AMG 820 in subjects with advanced solid tumors.
What is the current status of trial NCT01444404?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2008-03-31. Estimated completion is 2014-02-06.
What conditions does trial NCT01444404 study?
This clinical trial studies the following conditions: Cancer, Advanced Solid Tumors, Oncology, Tumors, Oncology Patients.
What interventions are being tested in trial NCT01444404?
The interventions under investigation include: AMG 820 (DRUG).
Who is sponsoring clinical trial NCT01444404?
This trial is sponsored by AmMax Bio, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01444404 being conducted?
This trial has 3 study locations across Pennsylvania, South Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01444404's enrollment target sits among peer trials
25 537th of 615 higher than 71 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Impact of Daily Oral Cannabis Doses in Patients With Cancer
RECRUITING · Phase 1
-
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI